Anti-Itch side effects: what 66,627 FDA adverse event reports show

Anti-Itch · Hydrocortisone · 1,243 reaction terms · 478,527 drug–reaction co-reports · data 2026-09-14

Drug class

Not stated in label

Brand names

Hydrocortisone

openFDA label

Who reports

66,627 reports · 83% serious · 9,795 with death outcome · 58% female

openFDA FAERS counts, all years, deduplication not applied

Used for

For temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to eczema, insect bites, poison ivy, poison oak, poison sumak, soaps, detergents, cosmetics, jewelry, seborrheic dermatitis, psoriasis and for external genital, feminine and anal itching

FDA label, Indications and Usage

What it is

Cortisol is a 17alpha-hydroxy-C21-steroid that is pregn-4-ene substituted by oxo groups at positions 3 and 20 and hydroxy groups at positions 11, 17 and 21.

PubChem CID 5754 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Reporting / coding artifact 1Lab value / disease marker 8No label text to screen 31

What the badges mean

Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,203 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Human bocavirus infection	113	466.3 348.3–624.3ROR 467.1 · calibrated p 3e-13 ✓	180.9 EB05 154.6 · IC025 +6.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=113 · ♀ 100% (drug 58%)	no trial arm names this drug
Lymphoid tissue hypoplasia	68	266.4 192.6–368.4ROR 266.6 · calibrated p 9e-11 ✓	138.1 EB05 112.7 · IC025 +5.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=68	no trial arm names this drug
Vaginal flatulence	138	260.4 207.7–326.5ROR 260.9 · calibrated p 6e-11 ✓	139.2 EB05 120.7 · IC025 +6.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=138 · ♀ 100% (drug 58%)	no trial arm names this drug
Thymus hypoplasia	73	232.9 171.9–315.5ROR 233.2 · calibrated p 2e-10 ✓	128.9 EB05 105.9 · IC025 +5.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=73	no trial arm names this drug
C-reactive protein	343	191.9 167.8–219.6ROR 192.9 · calibrated p 6e-10 ✓	118.1 EB05 108.0 · IC025 +6.5 3/3 methods agree	Lab value / disease marker	serious n=343 · ♀ 100% (drug 58%) · 95% clinician	no trial arm names this drug
Grip strength	87	189.6 145.2–247.6ROR 189.9 · calibrated p 1e-9 ✓	115.0 EB05 96.1 · IC025 +5.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=87 · ♀ 100% (drug 58%) · 100% clinician	no trial arm names this drug
Topical steroid withdrawal reaction	143	187.5 152.4–230.8ROR 187.9 · calibrated p 1e-9 ✓	115.4 EB05 100.4 · IC025 +6.1 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=139 · ♀ 79% (drug 58%) · 100% consumer	no trial arm names this drug
Deep vein thrombosis postoperative	723	184.5 168.3–202.2ROR 186.5 · calibrated p 8e-10 ✓	115.6 EB05 108.7 · IC025 +6.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=723 · ♀ 100% (drug 58%) · 91% clinician	no trial arm names this drug
Lupus vulgaris	430	178.6 158.7–201.1ROR 179.8 · calibrated p 1e-9 ✓	113.1 EB05 104.4 · IC025 +6.5 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=430 · ♀ 100% (drug 58%) · 95% clinician	no trial arm names this drug
Rheumatic fever	1,490	163.4 153.5–173.9ROR 167.1 · calibrated p 2e-9 ✓	107.1 EB05 102.6 · IC025 +6.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=1,490 · ♀ 100% (drug 58%) · 94% clinician	no trial arm names this drug
Swollen joint count increased	1,048	159.7 148.3–172.0ROR 162.2 · calibrated p 2e-9 ✓	105.5 EB05 100.2 · IC025 +6.6 3/3 methods agree	Lab value / disease marker	serious n=1,048 · ♀ 100% (drug 58%) · 95% clinician	no trial arm names this drug
Anti-cyclic citrullinated peptide antibody	221	156.1 132.9–183.5ROR 156.7 · calibrated p 4e-9 ✓	103.2 EB05 92.3 · IC025 +6.2 3/3 methods agree	Lab value / disease marker	serious n=221 · ♀ 100% (drug 58%) · 100% clinician	no trial arm names this drug
Facet joint syndrome	1,018	150.4 139.6–162.1ROR 152.8 · calibrated p 4e-9 ✓	101.4 EB05 96.3 · IC025 +6.5 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=1,018 · ♀ 100% (drug 58%) · 94% clinician	no trial arm names this drug
Cystitis bacterial	96	123.8 97.7–156.8ROR 124.0 · calibrated p 3e-8 ✓	87.2 EB05 73.5 · IC025 +5.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=96	no trial arm names this drug
Adjustment disorder with depressed mood	558	120.6 109.4–132.9ROR 121.6 · calibrated p 3e-8 ✓	86.8 EB05 80.9 · IC025 +6.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=558 · ♀ 100% (drug 58%) · 95% clinician	no trial arm names this drug
Swollen joint count	68	120.3 90.9–159.1ROR 120.4 · calibrated p 5e-8 ✓	84.9 EB05 69.3 · IC025 +5.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=68 · ♀ 100% (drug 58%) · 100% clinician	no trial arm names this drug
Norovirus test positive	88	117.4 91.9–150.0ROR 117.5 · calibrated p 5e-8 ✓	83.9 EB05 70.2 · IC025 +5.5 3/3 methods agree	Lab value / disease marker	serious n=88	no trial arm names this drug
X-ray abnormal	441	103.3 92.8–115.0ROR 104.0 · calibrated p 9e-8 ✓	77.5 EB05 71.6 · IC025 +6.0 3/3 methods agree	Lab value / disease marker	serious n=441 · ♀ 100% (drug 58%) · 95% clinician	no trial arm names this drug
Dislocation of vertebra	548	102.9 93.5–113.3ROR 103.8 · calibrated p 9e-8 ✓	77.3 EB05 72.0 · IC025 +6.0 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=548 · ♀ 100% (drug 58%) · 93% clinician	no trial arm names this drug
Steroid dependence	209	102.7 87.8–120.0ROR 103.0 · calibrated p 1e-7 ✓	76.8 EB05 68.5 · IC025 +5.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=208 · ♀ 27% (drug 58%)	no trial arm names this drug
Subcutaneous drug absorption impaired	134	102.6 84.4–124.8ROR 102.9 · calibrated p 1e-7 ✓	76.5 EB05 66.2 · IC025 +5.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=134 · ♀ 100% (drug 58%) · 100% clinician	no trial arm names this drug
Duodenal ulcer perforation	1,804	102.6 97.3–108.1ROR 105.4 · calibrated p 8e-8 ✓	77.2 EB05 74.3 · IC025 +6.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 53.6 · ♀ 100% (drug 58%) · 93% clinician	no trial arm names this drug
Anti-cyclic citrullinated peptide antibody positive	1,732	101.5 96.1–107.1ROR 104.1 · calibrated p 8e-8 ✓	76.6 EB05 73.6 · IC025 +6.1 3/3 methods agree	Lab value / disease marker	serious PRR 53.4 · ♀ 100% (drug 58%) · 93% clinician	no trial arm names this drug
Rheumatoid factor positive	1,359	97.0 91.3–103.0ROR 99.0 · calibrated p 1e-7 ✓	74.0 EB05 70.8 · IC025 +6.1 3/3 methods agree	Lab value / disease marker	serious n=1,359 · ♀ 100% (drug 58%) · 94% clinician	no trial arm names this drug
Steroid withdrawal syndrome	232	92.9 80.2–107.5ROR 93.2 · calibrated p 2e-7 ✓	71.3 EB05 63.9 · IC025 +5.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=232 · ♀ 82% (drug 58%)	no trial arm names this drug
Craniopharyngioma	74	88.4 68.3–114.5ROR 88.5 · calibrated p 4e-7 ✓	67.8 EB05 55.8 · IC025 +5.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=73 · 100% clinician	no trial arm names this drug
Adrenocortical insufficiency acute	414	86.6 77.7–96.6ROR 87.2 · calibrated p 3e-7 ✓	67.7 EB05 62.4 · IC025 +5.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=409	no trial arm names this drug
Retinitis	345	81.9 72.8–92.2ROR 82.4 · calibrated p 5e-7 ✓	64.8 EB05 59.2 · IC025 +5.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=345 · ♀ 100% (drug 58%) · 93% clinician	no trial arm names this drug
Mycobacterium chelonae infection	152	81.8 68.4–97.8ROR 82.0 · calibrated p 6e-7 ✓	64.4 EB05 56.3 · IC025 +5.5 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=152	no trial arm names this drug
Appendicolith	75	77.4 60.1–99.6ROR 77.5 · calibrated p 1e-6 ✓	61.2 EB05 50.4 · IC025 +5.1 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=75 · ♀ 0% (drug 58%) · 100% clinician	no trial arm names this drug
Peripheral venous disease	760	73.9 68.3–80.0ROR 74.8 · calibrated p 1e-6 ✓	59.8 EB05 56.3 · IC025 +5.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=757 · ♀ 100% (drug 58%) · 91% clinician	no trial arm names this drug
Analgesic therapy	58	73.3 55.0–97.5ROR 73.3 · calibrated p 2e-6 ✓	58.3 EB05 46.8 · IC025 +4.9 3/3 methods agree	Reporting / coding artifact	serious n=58 · ♀ 0% (drug 58%) · 100% clinician	no trial arm names this drug
Hypocholesterolaemia	58	73.0 54.8–97.1ROR 73.0 · calibrated p 2e-6 ✓	58.2 EB05 46.6 · IC025 +4.9 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=58 · ♀ 100% (drug 58%) · 100% clinician	no trial arm names this drug
Secondary immunodeficiency	222	71.8 62.0–83.1ROR 72.0 · calibrated p 1e-6 ✓	58.2 EB05 52.0 · IC025 +5.5 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=221 · ♀ 100% (drug 58%)	no trial arm names this drug
Catarrh	162	70.0 59.1–83.0ROR 70.2 · calibrated p 2e-6 ✓	56.9 EB05 49.9 · IC025 +5.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=162 · ♀ 0% (drug 58%)	no trial arm names this drug
Abscess bacterial	63	67.2 51.2–88.3ROR 67.3 · calibrated p 3e-6 ✓	54.5 EB05 44.1 · IC025 +4.9 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=63 · 100% clinician	no trial arm names this drug
Helicobacter infection	1,788	66.9 63.6–70.3ROR 68.7 · calibrated p 2e-6 ✓	55.1 EB05 53.0 · IC025 +5.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 40.4 · ♀ 100% (drug 58%) · 94% clinician	no trial arm names this drug
Adrenal suppression	147	66.3 55.5–79.2ROR 66.5 · calibrated p 2e-6 ✓	54.4 EB05 47.4 · IC025 +5.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=147	no trial arm names this drug
Pemphigus	1,984	59.7 56.9–62.6ROR 61.5 · calibrated p 4e-6 ✓	50.2 EB05 48.4 · IC025 +5.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 35.0 · ♀ 100% (drug 58%) · 93% clinician	no trial arm names this drug
C-reactive protein abnormal	1,003	58.3 54.6–62.4ROR 59.2 · calibrated p 5e-6 ✓	49.2 EB05 46.7 · IC025 +5.5 3/3 methods agree	Lab value / disease marker	serious n=1,003 · ♀ 100% (drug 58%) · 94% clinician	no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

Concept	Reports	PRR 95% CI	Reading
Liver injury	3,973	4.24.1–4.3	signal
Interstitial lung disease	1,251	4.13.9–4.4	signal
Hyponatraemia	1,000	3.93.7–4.2	signal
Neutropenia / agranulocytosis	2,491	3.23.1–3.3	signal
Serious infection	7,211	3.02.9–3.0	signal
Pancreatitis	713	2.82.6–3.0	signal
Hyperglycaemia / diabetes	2,997	2.72.6–2.8	signal
Anaphylaxis / angioedema	1,030	2.62.4–2.8	signal
Severe cutaneous reaction	608	2.62.4–2.8	signal
Opportunistic infection	1,077	2.52.4–2.7	signal
Gi bleeding	1,387	2.42.3–2.5	signal
Depression	1,962	2.22.1–2.3	signal
Rhabdomyolysis / myopathy	555	2.22.0–2.3	raised
Anaemia	2,022	2.12.0–2.2	signal
Thrombocytopenia	1,370	2.01.9–2.1	raised
Venous thromboembolism	1,319	1.91.8–2.0	raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Anti-Itch only as a background or rescue medication (NCT00153101, NCT02625181); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Off label use (used outside approved label)	9,444	3.5 3.4–3.5ROR 3.9 · calibrated p 0.405	3.4 EB05 3.4 · IC025 +1.7 3/3 methods agree	Reporting / coding artifact	age-adj. PRR 2.8 · serious PRR 4.1	no trial arm names this drug
Drug ineffective (drug did not work)	7,465	1.8 1.8–1.8ROR 1.9 · calibrated p 0.881	1.8 EB05 1.8 · IC025 +0.8	Reporting / coding artifact	age-adj. PRR 2.0 · serious PRR 2.9	no trial arm names this drug
Fatigue (tiredness)	5,918	2.4 2.3–2.5ROR 2.5 · calibrated p 0.794	2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 2.2 · serious PRR 2.7	no trial arm names this drug
Condition aggravated	5,454	5.8 5.6–5.9ROR 6.2 · calibrated p 0.138	5.7 EB05 5.6 · IC025 +2.5 3/3 methods agree	Reporting / coding artifact	age-adj. PRR 4.4 · serious PRR 5.7	no trial arm names this drug
Nausea	4,997	2.0 1.9–2.1ROR 2.1 · calibrated p 0.987	2.0 EB05 1.9 · IC025 +0.9	No label text to screen label has no adverse-reaction text	age-adj. PRR 1.8 · serious PRR 2.4	no trial arm names this drug
Rash	4,907	3.6 3.5–3.7ROR 3.8 · calibrated p 0.418	3.6 EB05 3.5 · IC025 +1.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 3.1 · serious PRR 4.6	no trial arm names this drug
Diarrhoea (diarrhea)	4,450	2.2 2.1–2.2ROR 2.3 · calibrated p 0.917	2.2 EB05 2.1 · IC025 +1.1 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 2.1 · serious PRR 2.3	no trial arm names this drug
Headache	4,424	2.2 2.2–2.3ROR 2.3 · calibrated p 0.894	2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 1.9 · serious PRR 2.8 · ♀ 80% (drug 58%)	no trial arm names this drug
Pain	4,422	2.3 2.2–2.3ROR 2.4 · calibrated p 0.875	2.3 EB05 2.2 · IC025 +1.1 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 2.3 · serious PRR 2.3 · ♀ 79% (drug 58%)	no trial arm names this drug
Arthralgia (joint pain)	4,293	3.3 3.2–3.4ROR 3.4 · calibrated p 0.499	3.3 EB05 3.2 · IC025 +1.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 2.7 · serious PRR 3.8 · ♀ 79% (drug 58%)	no trial arm names this drug
Dyspnoea (shortness of breath)	4,284	2.4 2.3–2.5ROR 2.5 · calibrated p 0.818	2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 2.2 · serious PRR 2.2	no trial arm names this drug
Pyrexia (fever)	3,968	3.6 3.5–3.7ROR 3.8 · calibrated p 0.416	3.6 EB05 3.5 · IC025 +1.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 2.7 · serious PRR 3.0	no trial arm names this drug
Vomiting	3,908	2.6 2.6–2.7ROR 2.7 · calibrated p 0.718	2.6 EB05 2.6 · IC025 +1.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 2.2 · serious PRR 2.6	no trial arm names this drug
Pruritus (itching)	3,691	3.1 3.0–3.2ROR 3.2 · calibrated p 0.560	3.1 EB05 3.0 · IC025 +1.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 2.5 · serious PRR 4.0	no trial arm names this drug
Malaise (feeling unwell)	3,612	2.6 2.5–2.7ROR 2.7 · calibrated p 0.736	2.6 EB05 2.5 · IC025 +1.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 2.6 · serious PRR 2.8 · ♀ 79% (drug 58%)	no trial arm names this drug

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Anti-Itch?

In FDA FAERS, the most frequently co-reported reaction terms for Anti-Itch are fatigue, nausea, rash, diarrhoea, headache, pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Anti-Itch have an FDA boxed warning?

No. The FDA label retrieved for Anti-Itch has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Anti-Itch causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 884c8227-b4f3-7ef1-e053-2995a90a0ee3, effective 20251125; matched on openfda.generic_name.exact:"ANTI-ITCH")
PubChem CID 5754 description (ChEBI)
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 1,243 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath
ClinicalTrials.gov API v2 (query ANTI-ITCH, results-bearing studies sorted by enrollment)

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.